PhageTech Inc.
This article was originally published in Start Up
Executive Summary
PhageTech is mining the genome of phage virus, which infect bacteria, for targets with which to create a new generation of antibiotics.
You may also be interested in...
Drug Resistance Start-Ups: Is Resistance Futile?
Overcoming drug resistance is a key goal of development--but will anyone fund it?
Thios Pharmaceuticals Inc.
Sulfation is the process in which sulfate recovered by cells from the bloodstream is attached to target molecules, such as glycoproteins. Thios Pharmaceuticals, formed around its founders' sulfation research, believes these pathways will be fertile ground for identifying a new class of therapeutic targets.
Cyclis Pharmaceuticals Inc.
Normally during the cell cycle, molecular signaling checkpoints prevent cell division in the event of chromosomal shuffling or DNA damage. Cyclis Pharmaceuticals is developing cancer drugs that turn on the deactivated cellular surveillance system, leading to apoptosis and cell death.